2017
DOI: 10.1111/1471-0528.14646
|View full text |Cite
|
Sign up to set email alerts
|

A research agenda for moving early medical pregnancy termination over the counter

Abstract: Given the overall safety profile and increasing availability of medical pregnancy termination drugs, we asked: would the mifepristone–misoprostol regimen for medical termination at ≤10 weeks of gestation meet US Food and Drug Administration regulatory criteria for over‐the‐counter (OTC) approval, and if not, what are the present research gaps? We conducted a literature review of consumer behaviours necessary for a successful OTC application for medical termination at ≤10 weeks of gestation and identified cruci… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
17
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 24 publications
(17 citation statements)
references
References 34 publications
(57 reference statements)
0
17
0
Order By: Relevance
“…Some women may prefer full medical supervision and support, while others may prefer an autonomous process; still others may prefer something in between. The diversity of reasons we found for seeking to self‐manage supports prior work advocating for abortion medications to be available over the counter in pharmacies and through a variety of clinical telemedicine models . We hope that they also inspire creative thinking about how providers and public health practitioners can design and implement new models that ensure safe, supported and accessible abortion care for all.…”
Section: Resultsmentioning
confidence: 52%
See 1 more Smart Citation
“…Some women may prefer full medical supervision and support, while others may prefer an autonomous process; still others may prefer something in between. The diversity of reasons we found for seeking to self‐manage supports prior work advocating for abortion medications to be available over the counter in pharmacies and through a variety of clinical telemedicine models . We hope that they also inspire creative thinking about how providers and public health practitioners can design and implement new models that ensure safe, supported and accessible abortion care for all.…”
Section: Resultsmentioning
confidence: 52%
“…Moreover, not all who encounter such barriers are able to overcome them. Indeed, two medications to be available over the counter in pharmacies 34 and through a variety of clinical telemedicine models. 35,36 We hope that they also inspire creative thinking about how providers and public health practitioners can design and implement new models that ensure safe, supported and accessible abortion care for all.…”
Section: Discussionmentioning
confidence: 99%
“…In 2014, nearly one third (31%) of nonhospital abortions were performed with medications [1]. While MA meets most of the Food and Drug Administration criteria for over-the-counter (OTC) approval, including its low toxicity, low potential for abuse and nonaddictiveness [2], access to the method remains restricted. In the United States, women are required to obtain mifepristone in a medical facility such as a doctor's office, clinic or hospital, even though they are allowed to take it at home [3,4].…”
Section: Introductionmentioning
confidence: 99%
“…Increasingly, women in the United States are obtaining MA through nontraditional routes including online or through telemedicine services, particularly where access is difficult [2,15,16]. Those who self-manage their abortions outside of the formal health care setting presumably do so because they prefer its privacy and convenience and/or face barriers accessing care [17][18][19][20].…”
Section: Introductionmentioning
confidence: 99%
“… 7 , 8 Aside being approved for clinical use for over a decade, it is also recommended for use by the World Health Organization (WHO) and other key global reproductive health bodies. 9 , 10 …”
Section: Introductionmentioning
confidence: 99%